Clinically relevant genetic variations in drug metabolizing enzymes.
Clinically relevant genetic variations in drug metabolizing enzymes.
复制标题
DOI：
10.2174/138920011795495321
复制
发表时间：
2011-06
影响因子：
2.3
通讯作者：
Dolan ME
中科院分区：
文献类型：
--
作者：
Pinto N;Dolan ME
在药物遗传学领域，我们目前有一些标志物可以指导医生为患者提供最佳治疗方案。大多数情况下，这些遗传变异位于药物代谢酶内，对药物转化为其代谢物的程度或速率有很大影响。对于许多药物来说，反应和毒性是多基因特征，了解患者药物代谢酶的遗传变异与药物的功效和/或毒性之间的关系提供了优化治疗的潜力。本综述将重点关注对药物功效和/或毒性具有可预测且相对较大影响的药物代谢酶变异；其中一些药物/基因变异对影响了美国食品和药物管理局的药物标签。将讨论识别遗传标记和根据已知标记实施临床改变的挑战。此外，还将讨论下一代测序在识别罕见变异方面的影响。
In the field of pharmacogenetics, we currently have a few markers to guide physicians as to the best course of therapy for patients. For the most part, these genetic variants are within a drug metabolizing enzyme that has a large effect on the degree or rate at which a drug is converted to its metabolites. For many drugs, response and toxicity are multi-genic traits and understanding relationships between a patient's genetic variation in drug metabolizing enzymes and the efficacy and/or toxicity of a medication offers the potential to optimize therapies. This review will focus on variants in drug metabolizing enzymes with predictable and relatively large impacts on drug efficacy and/or toxicity; some of these drug/gene variant pairs have impacted drug labels by the United States Food and Drug Administration. The challenges in identifying genetic markers and implementing clinical changes based on known markers will be discussed. In addition, the impact of next generation sequencing in identifying rare variants will be addressed.
登录
查看更多内容
影响因子：
6.1
作者：
BERTILSSON, L;EICHELBAUM, M;SJOQVIST, F
通讯作者：
SJOQVIST, F
影响因子：
82.9
作者：
Bouman, Heleen J.;Schoemig, Edgar;Taubert, Dirk
通讯作者：
Taubert, Dirk
影响因子：
2.6
作者：
Black WJ;Stagos D;Marchitti SA;Nebert DW;Tipton KF;Bairoch A;Vasiliou V
通讯作者：
Vasiliou V
影响因子：
6.7
作者：
Benowitz, Neal L.;Swan, Gary E.;Tyndale, Rachel F.
通讯作者：
Tyndale, Rachel F.
DOI：
10.1001/jama.1952.72930340022010b
发表时间：
1952-01-01
影响因子：
120.7
作者：
CLAYMAN, CB;ARNOLD, J;ALVING, AS
通讯作者：
ALVING, AS